What we offer
We currently provide around 155 pharmaceutical products for human use to pharmaceutical companies, mainly in the form of tablets, capsules and injections. The R&D specialists we collaborate with at Teva, our parent company, maintain a strong development pipeline, enabling the timely availability of new products for our customers.
We have also established our company as a reliable source of pharmaceutical intellectual property in the form of comprehensive registration dossiers. We have a solid track record of securing regulatory approval prior to patent expiries. Our vast experience in launching new products and our proven regulatory skills contribute to a highly successful approach, which gets results fast.
Medis has obtained marketing authorisations in over 140 countries to date and exports to most European nations, as well as other regions of the world.
Oncology products – Quality dossiers
Featured in our comprehensive portfolio is a growing range of specialist oncology products with even more dossiers are expected to be completed over the next few years.
We have established a number of partnerships with pharmaceutical companies dedicated to the hospital market. So, if your current or future business strategy includes a focus on hospital markets and oncology products, please contact us for further information and advice.
Product formulations include modified release, solid oral dosage, semi-solids, suspensions, transdermals, suppositories, creams, ointments, liquids and injectables.
For more information on all available products and dossiers, and our development pipeline, please email firstname.lastname@example.org.